Literature DB >> 30936020

Macrophage-targeted, enzyme-triggered fluorescence switch-on system for detection of embolism-vulnerable atherosclerotic plaques.

Yudai Narita1, Kosuke Shimizu2, Keisuke Ikemoto3, Ryuji Uchino4, Mutsumi Kosugi4, Marten B Maess4, Yasuhiro Magata4, Naoto Oku5, Mikako Ogawa6.   

Abstract

The development of atherosclerotic plaques is a critical step that can result in an arterial embolism. Therefore, detection of these vulnerable plaques is of clinical significance for the diagnosis of atherosclerosis. However, there are few imaging systems able to detect such plaques easily. In this study, we designed a new platform for near-infrared fluorescence (NIRF) imaging of macrophages in atherosclerotic plaques, one using both a liposomal DDS and an activatable fluorescent probe, and evaluated the utility of this imaging for the diagnosis of atherosclerosis. We first synthesized a fluorescent switch-on probe, Peptide-ICG2, which is optically silent under normal conditions but activated in the presence of the lysosomal enzyme, cathepsin B. To achieve macrophage-specific fluorescence activation, we encapsulated Peptide-ICG2 into phosphatidylserine-containing liposome (P-ICG2-PS-Lip), since the accumulation of phosphatidylserine receptor-bearing macrophages is characteristic of embolism-vulnerable plaques. The experiments using macrophage-like RAW264 cells in culture showed that P-ICG2-PS-Lip was selectively taken up into the cells and that significant fluorescence of the probe was observed. For NIRF imaging of the atherosclerotic plaques, P-ICG2-PS-Lip was intravenously injected into ApoE-knockout atherosclerotic model mice or WHHL rabbits, and the fluorescence at the aortae was imaged. The results indicated that ICG fluorescence could be successfully observed at the plaques on the artery walls. The results of the present study thus suggest that NIRF imaging using P-ICG2-PS-Lip would be useful for detecting embolism-vulnerable atherosclerotic plaques.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Atherosclerotic vulnerable plaque; Cathepsin B; Fluorescence imaging; Liposome; Macrophage; Phosphatidylserine

Year:  2019        PMID: 30936020     DOI: 10.1016/j.jconrel.2019.03.025

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  9 in total

1.  Targeting Peptide, Fluorescent Reagent Modified Magnetic Liposomes Coated with Rapamycin Target Early Atherosclerotic Plaque and Therapy.

Authors:  Chen Huang; Wentao Huang; Lifen Zhang; Chunyu Zhang; Chengqian Zhou; Wei Wei; Yongsheng Li; Quan Zhou; Wenli Chen; Yukuan Tang
Journal:  Pharmaceutics       Date:  2022-05-18       Impact factor: 6.525

Review 2.  Recent advances in nanomaterials for therapy and diagnosis for atherosclerosis.

Authors:  Jun Chen; Xixi Zhang; Reid Millican; Jennifer Sherwood; Sean Martin; Hanjoong Jo; Young-Sup Yoon; Brigitta C Brott; Ho-Wook Jun
Journal:  Adv Drug Deliv Rev       Date:  2021-01-09       Impact factor: 15.470

Review 3.  Nanosystems as Vehicles for the Delivery of Antimicrobial Peptides (AMPs).

Authors:  Ángela Martin-Serrano; Rafael Gómez; Paula Ortega; F Javier de la Mata
Journal:  Pharmaceutics       Date:  2019-09-02       Impact factor: 6.321

Review 4.  Nanotechnology for cardiovascular diseases.

Authors:  Qinqin Hu; Zheyan Fang; Junbo Ge; Hua Li
Journal:  Innovation (Camb)       Date:  2022-02-02

Review 5.  Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis.

Authors:  Wei Chen; Maaike Schilperoort; Yihai Cao; Jinjun Shi; Ira Tabas; Wei Tao
Journal:  Nat Rev Cardiol       Date:  2021-11-10       Impact factor: 49.421

6.  LIFU-responsive nanomedicine enables acoustic droplet vaporization-induced apoptosis of macrophages for stabilizing vulnerable atherosclerotic plaques.

Authors:  Jingxin Hou; Jun Zhou; Meiqi Chang; Guangcheng Bao; Jie Xu; Man Ye; Yixin Zhong; Shuling Liu; Junrui Wang; Wei Zhang; Haitao Ran; Zhigang Wang; Yu Chen; Dajing Guo
Journal:  Bioact Mater       Date:  2022-03-03

Review 7.  Macrophage-targeted nanomedicine for the diagnosis and management of atherosclerosis.

Authors:  Ping Ping Hu; Shuang Xue Luo; Xiao Qing Fan; Di Li; Xiao Yong Tong
Journal:  Front Pharmacol       Date:  2022-09-09       Impact factor: 5.988

Review 8.  Molecular and Nonmolecular Imaging of Macrophages in Atherosclerosis.

Authors:  Zhaoyue Li; Hao Tang; Yingfeng Tu
Journal:  Front Cardiovasc Med       Date:  2021-05-19

Review 9.  Enzyme-activated probes in optical imaging: a focus on atherosclerosis.

Authors:  Edward R H Walter; Saul M Cooper; Joseph J Boyle; Nicholas J Long
Journal:  Dalton Trans       Date:  2021-10-26       Impact factor: 4.390

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.